Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 103

1.

Tumor Microvessel Density as a Prognostic Marker in High-Risk Renal Cell Carcinoma Patients Treated on ECOG-ACRIN E2805.

Jilaveanu LB, Puligandla M, Weiss SA, Wang XV, Zito C, Flaherty KT, Boeke M, Neumeister V, Camp RL, Adeniran A, Pins M, Manola J, DiPaola RS, Haas NB, Kluger HM.

Clin Cancer Res. 2018 Jan 1;24(1):217-223. doi: 10.1158/1078-0432.CCR-17-1555. Epub 2017 Oct 24.

PMID:
29066509
2.

Characterization of tumor infiltrating lymphocytes in paired primary and metastatic renal cell carcinoma specimens.

Baine MK, Turcu G, Zito CR, Adeniran AJ, Camp RL, Chen L, Kluger HM, Jilaveanu LB.

Oncotarget. 2015 Sep 22;6(28):24990-5002. doi: 10.18632/oncotarget.4572.

3.

PAX-8 expression in renal tumours and distant sites: a useful marker of primary and metastatic renal cell carcinoma?

Barr ML, Jilaveanu LB, Camp RL, Adeniran AJ, Kluger HM, Shuch B.

J Clin Pathol. 2015 Jan;68(1):12-7. doi: 10.1136/jclinpath-2014-202259. Epub 2014 Oct 14.

4.

NY-ESO-1 as a potential immunotherapeutic target in renal cell carcinoma.

Giesen E, Jilaveanu LB, Parisi F, Kluger Y, Camp RL, Kluger HM.

Oncotarget. 2014 Jul 30;5(14):5209-17.

5.

Microvessel area as a predictor of sorafenib response in metastatic renal cell carcinoma.

Aziz SA, Sznol JA, Albiges L, Zito C, Jilaveanu LB, Camp RL, Escudier B, Kluger HM.

Cancer Cell Int. 2014 Jan 14;14(1):4. doi: 10.1186/1475-2867-14-4.

6.

Expression of drug targets in primary and matched metastatic renal cell carcinoma tumors.

Aziz SA, Sznol JA, Adeniran A, Parisi F, Kluger Y, Camp RL, Kluger HM.

BMC Clin Pathol. 2013 Feb 1;13:3. doi: 10.1186/1472-6890-13-3.

7.

Vascularity of primary and metastatic renal cell carcinoma specimens.

Aziz SA, Sznol J, Adeniran A, Colberg JW, Camp RL, Kluger HM.

J Transl Med. 2013 Jan 14;11:15. doi: 10.1186/1479-5876-11-15.

8.

c-Met is a prognostic marker and potential therapeutic target in clear cell renal cell carcinoma.

Gibney GT, Aziz SA, Camp RL, Conrad P, Schwartz BE, Chen CR, Kelly WK, Kluger HM.

Ann Oncol. 2013 Feb;24(2):343-9. doi: 10.1093/annonc/mds463. Epub 2012 Sep 28.

9.

Quantitative assessment of invasive mena isoforms (Menacalc) as an independent prognostic marker in breast cancer.

Agarwal S, Gertler FB, Balsamo M, Condeelis JS, Camp RL, Xue X, Lin J, Rohan TE, Rimm DL.

Breast Cancer Res. 2012 Sep 12;14(5):R124. doi: 10.1186/bcr3318.

10.

CD70 expression patterns in renal cell carcinoma.

Jilaveanu LB, Sznol J, Aziz SA, Duchen D, Kluger HM, Camp RL.

Hum Pathol. 2012 Sep;43(9):1394-9. doi: 10.1016/j.humpath.2011.10.014. Epub 2012 Mar 7.

11.

Punctate LC3B expression is a common feature of solid tumors and associated with proliferation, metastasis, and poor outcome.

Lazova R, Camp RL, Klump V, Siddiqui SF, Amaravadi RK, Pawelek JM.

Clin Cancer Res. 2012 Jan 15;18(2):370-9. doi: 10.1158/1078-0432.CCR-11-1282. Epub 2011 Nov 11.

12.

Evaluation of prognostic and predictive value of microtubule associated protein tau in two independent cohorts.

Baquero MT, Lostritto K, Gustavson MD, Bassi KA, Appia F, Camp RL, Molinaro AM, Harris LN, Rimm DL.

Breast Cancer Res. 2011 Nov 2;13(5):R85. doi: 10.1186/bcr2937.

13.

Lymph node ratio should be considered for incorporation into staging for breast cancer.

Chagpar AB, Camp RL, Rimm DL.

Ann Surg Oncol. 2011 Oct;18(11):3143-8. doi: 10.1245/s10434-011-2012-9. Epub 2011 Aug 17.

PMID:
21847696
14.

Quantitative assessment shows loss of antigenic epitopes as a function of pre-analytic variables.

Bai Y, Tolles J, Cheng H, Siddiqui S, Gopinath A, Pectasides E, Camp RL, Rimm DL, Molinaro AM.

Lab Invest. 2011 Aug;91(8):1253-61. doi: 10.1038/labinvest.2011.75. Epub 2011 Apr 25.

15.

In vitro studies of dasatinib, its targets and predictors of sensitivity.

Jilaveanu LB, Zito CR, Aziz SA, Chakraborty A, Davies MA, Camp RL, Rimm DL, Dudek A, Sznol M, Kluger HM.

Pigment Cell Melanoma Res. 2011 Apr;24(2):386-9. doi: 10.1111/j.1755-148X.2011.00835.x. No abstract available.

16.

Vertical targeting of the phosphatidylinositol-3 kinase pathway as a strategy for treating melanoma.

Aziz SA, Jilaveanu LB, Zito C, Camp RL, Rimm DL, Conrad P, Kluger HM.

Clin Cancer Res. 2010 Dec 15;16(24):6029-39. doi: 10.1158/1078-0432.CCR-10-1490.

17.

Benefits of biomarker selection and clinico-pathological covariate inclusion in breast cancer prognostic models.

Parisi F, Gonzalez AM, Nadler Y, Camp RL, Rimm DL, Kluger HM, Kluger Y.

Breast Cancer Res. 2010;12(5):R66. doi: 10.1186/bcr2633. Epub 2010 Sep 1.

18.

Automated analysis of tissue microarrays.

Dolled-Filhart M, Gustavson M, Camp RL, Rimm DL, Tonkinson JL, Christiansen J.

Methods Mol Biol. 2010;664:151-62. doi: 10.1007/978-1-60761-806-5_15.

PMID:
20690061
19.

In situ identification of putative cancer stem cells by multiplexing ALDH1, CD44, and cytokeratin identifies breast cancer patients with poor prognosis.

Neumeister V, Agarwal S, Bordeaux J, Camp RL, Rimm DL.

Am J Pathol. 2010 May;176(5):2131-8. doi: 10.2353/ajpath.2010.090712. Epub 2010 Mar 12.

20.

The CCK(2) receptor antagonist, YF476, inhibits Mastomys ECL cell hyperplasia and gastric carcinoid tumor development.

Kidd M, Siddique ZL, Drozdov I, Gustafsson BI, Camp RL, Black JW, Boyce M, Modlin IM.

Regul Pept. 2010 Jun 8;162(1-3):52-60. doi: 10.1016/j.regpep.2010.01.009. Epub 2010 Feb 6.

PMID:
20144901
21.

Quantitative expression of VEGF, VEGF-R1, VEGF-R2, and VEGF-R3 in melanoma tissue microarrays.

Mehnert JM, McCarthy MM, Jilaveanu L, Flaherty KT, Aziz S, Camp RL, Rimm DL, Kluger HM.

Hum Pathol. 2010 Mar;41(3):375-84. doi: 10.1016/j.humpath.2009.08.016. Epub 2009 Dec 11.

22.

Melanoma prognostic model using tissue microarrays and genetic algorithms.

Gould Rothberg BE, Berger AJ, Molinaro AM, Subtil A, Krauthammer MO, Camp RL, Bradley WR, Ariyan S, Kluger HM, Rimm DL.

J Clin Oncol. 2009 Dec 1;27(34):5772-80. doi: 10.1200/JCO.2009.22.8239. Epub 2009 Nov 2.

23.

C-Raf is associated with disease progression and cell proliferation in a subset of melanomas.

Jilaveanu LB, Zito CR, Aziz SA, Conrad PJ, Schmitz JC, Sznol M, Camp RL, Rimm DL, Kluger HM.

Clin Cancer Res. 2009 Sep 15;15(18):5704-13. doi: 10.1158/1078-0432.CCR-09-0198. Epub 2009 Sep 8.

24.

Growth factor receptor-bound protein-7 (Grb7) as a prognostic marker and therapeutic target in breast cancer.

Nadler Y, González AM, Camp RL, Rimm DL, Kluger HM, Kluger Y.

Ann Oncol. 2010 Mar;21(3):466-73. doi: 10.1093/annonc/mdp346. Epub 2009 Aug 28.

25.

Defining molecular phenotypes of human papillomavirus-associated oropharyngeal squamous cell carcinoma: validation of three-class hypothesis.

Weinberger PM, Yu Z, Kountourakis P, Sasaki C, Haffty BG, Kowalski D, Merkley MA, Rimm DL, Camp RL, Psyrri A.

Otolaryngol Head Neck Surg. 2009 Sep;141(3):382-9. doi: 10.1016/j.otohns.2009.04.014.

PMID:
19716018
26.

Phosphatidylinositol-3-kinase as a therapeutic target in melanoma.

Aziz SA, Davies M, Pick E, Zito C, Jilaveanu L, Camp RL, Rimm DL, Kluger Y, Kluger HM.

Clin Cancer Res. 2009 May 1;15(9):3029-36. doi: 10.1158/1078-0432.CCR-08-2768. Epub 2009 Apr 21.

27.

Quantitative multiplexed analysis of ErbB family coexpression for primary breast cancer prognosis in a large retrospective cohort.

Giltnane JM, Moeder CB, Camp RL, Rimm DL.

Cancer. 2009 Jun 1;115(11):2400-9. doi: 10.1002/cncr.24277.

28.

Expression and prognostic significance of kallikrein-related peptidase 8 protein levels in advanced ovarian cancer by using automated quantitative analysis.

Kountourakis P, Psyrri A, Scorilas A, Markakis S, Kowalski D, Camp RL, Diamandis EP, Dimopoulos MA.

Thromb Haemost. 2009 Mar;101(3):541-6.

PMID:
19277417
29.

Predicting neuroendocrine tumor (carcinoid) neoplasia using gene expression profiling and supervised machine learning.

Drozdov I, Kidd M, Nadler B, Camp RL, Mane SM, Hauso O, Gustafsson BI, Modlin IM.

Cancer. 2009 Apr 15;115(8):1638-50. doi: 10.1002/cncr.24180.

30.

Expression of sorafenib targets in melanoma patients treated with carboplatin, paclitaxel and sorafenib.

Jilaveanu L, Zito C, Lee SJ, Nathanson KL, Camp RL, Rimm DL, Flaherty KT, Kluger HM.

Clin Cancer Res. 2009 Feb 1;15(3):1076-85. doi: 10.1158/1078-0432.CCR-08-2280.

31.

Analysis of Drosophila segmentation network identifies a JNK pathway factor overexpressed in kidney cancer.

Liu J, Ghanim M, Xue L, Brown CD, Iossifov I, Angeletti C, Hua S, Nègre N, Ludwig M, Stricker T, Al-Ahmadie HA, Tretiakova M, Camp RL, Perera-Alberto M, Rimm DL, Xu T, Rzhetsky A, White KP.

Science. 2009 Feb 27;323(5918):1218-22. doi: 10.1126/science.1157669. Epub 2009 Jan 22.

32.

AQUA analysis of thymidylate synthase reveals localization to be a key prognostic biomarker in 2 large cohorts of colorectal carcinoma.

Gustavson MD, Molinaro AM, Tedeschi G, Camp RL, Rimm DL.

Arch Pathol Lab Med. 2008 Nov;132(11):1746-52. doi: 10.1043/1543-2165-132.11.1746.

PMID:
18976010
33.

A decade of tissue microarrays: progress in the discovery and validation of cancer biomarkers.

Camp RL, Neumeister V, Rimm DL.

J Clin Oncol. 2008 Dec 1;26(34):5630-7. doi: 10.1200/JCO.2008.17.3567. Epub 2008 Oct 20. Review.

PMID:
18936473
34.

Microvessel area using automated image analysis is reproducible and is associated with prognosis in breast cancer.

Sullivan CA, Ghosh S, Ocal IT, Camp RL, Rimm DL, Chung GG.

Hum Pathol. 2009 Feb;40(2):156-65. doi: 10.1016/j.humpath.2008.07.005. Epub 2008 Sep 16.

PMID:
18799189
35.

High levels of vascular endothelial growth factor and its receptors (VEGFR-1, VEGFR-2, neuropilin-1) are associated with worse outcome in breast cancer.

Ghosh S, Sullivan CA, Zerkowski MP, Molinaro AM, Rimm DL, Camp RL, Chung GG.

Hum Pathol. 2008 Dec;39(12):1835-43. doi: 10.1016/j.humpath.2008.06.004. Epub 2008 Aug 20.

36.

Expression of Aurora A (but not Aurora B) is predictive of survival in breast cancer.

Nadler Y, Camp RL, Schwartz C, Rimm DL, Kluger HM, Kluger Y.

Clin Cancer Res. 2008 Jul 15;14(14):4455-62. doi: 10.1158/1078-0432.CCR-07-5268.

37.

Classification of renal cell carcinoma based on expression of VEGF and VEGF receptors in both tumor cells and endothelial cells.

Kluger HM, Siddiqui SF, Angeletti C, Sznol M, Kelly WK, Molinaro AM, Camp RL.

Lab Invest. 2008 Sep;88(9):962-72. doi: 10.1038/labinvest.2008.65. Epub 2008 Jul 14.

38.

Estrogen receptor co-activator (AIB1) protein expression by automated quantitative analysis (AQUA) in a breast cancer tissue microarray and association with patient outcome.

Harigopal M, Heymann J, Ghosh S, Anagnostou V, Camp RL, Rimm DL.

Breast Cancer Res Treat. 2009 May;115(1):77-85. doi: 10.1007/s10549-008-0063-9. Epub 2008 Jun 3.

PMID:
18521745
39.

Expression patterns and prognostic value of Bag-1 and Bcl-2 in breast cancer.

Nadler Y, Camp RL, Giltnane JM, Moeder C, Rimm DL, Kluger HM, Kluger Y.

Breast Cancer Res. 2008;10(2):R35. doi: 10.1186/bcr1998. Epub 2008 Apr 23.

40.

Quantitative justification of the change from 10% to 30% for human epidermal growth factor receptor 2 scoring in the American Society of Clinical Oncology/College of American Pathologists guidelines: tumor heterogeneity in breast cancer and its implications for tissue microarray based assessment of outcome.

Moeder CB, Giltnane JM, Harigopal M, Molinaro A, Robinson A, Gelmon K, Huntsman D, Camp RL, Rimm DL; American Society of Clinical Oncology; College of American Pathologists.

J Clin Oncol. 2007 Dec 1;25(34):5418-25.

PMID:
18048824
41.

HSP90 as a marker of progression in melanoma.

McCarthy MM, Pick E, Kluger Y, Gould-Rothberg B, Lazova R, Camp RL, Rimm DL, Kluger HM.

Ann Oncol. 2008 Mar;19(3):590-4. Epub 2007 Nov 23.

PMID:
18037622
42.

Bimodal population or pathologist artifact?

Rimm DL, Giltnane JM, Moeder C, Harigopal M, Chung GG, Camp RL, Burtness B.

J Clin Oncol. 2007 Jun 10;25(17):2487-8. No abstract available.

PMID:
17557963
43.
44.

High HSP90 expression is associated with decreased survival in breast cancer.

Pick E, Kluger Y, Giltnane JM, Moeder C, Camp RL, Rimm DL, Kluger HM.

Cancer Res. 2007 Apr 1;67(7):2932-7.

45.

Quantitative analysis of breast cancer tissue microarrays shows high cox-2 expression is associated with poor outcome.

Zerkowski MP, Camp RL, Burtness BA, Rimm DL, Chung GG.

Cancer Invest. 2007 Feb;25(1):19-26.

PMID:
17364553
46.

Quantitative analysis of estrogen receptor heterogeneity in breast cancer.

Chung GG, Zerkowski MP, Ghosh S, Camp RL, Rimm DL.

Lab Invest. 2007 Jul;87(7):662-9. Epub 2007 Mar 5.

47.

Antibody validation by quantitative analysis of protein expression using expression of Met in breast cancer as a model.

Pozner-Moulis S, Cregger M, Camp RL, Rimm DL.

Lab Invest. 2007 Mar;87(3):251-60. Epub 2007 Jan 29.

48.
49.

Analysis of p53 protein expression levels on ovarian cancer tissue microarray using automated quantitative analysis elucidates prognostic patient subsets.

Psyrri A, Kountourakis P, Yu Z, Papadimitriou C, Markakis S, Camp RL, Economopoulos T, Dimopoulos MA.

Ann Oncol. 2007 Apr;18(4):709-15. Epub 2007 Jan 13.

PMID:
17220511
50.

Classification of breast cancer using genetic algorithms and tissue microarrays.

Dolled-Filhart M, Rydén L, Cregger M, Jirström K, Harigopal M, Camp RL, Rimm DL.

Clin Cancer Res. 2006 Nov 1;12(21):6459-68.

Supplemental Content

Support Center